Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide

We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65 years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients received: i) continuous lenalidomide and low-dose dexamethasone until disease progression; ii) fixed cycles of...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Haematologica
Päätekijät: Delforge, Michel, Minuk, Leonard, Eisenmann, Jean-Claude, Arnulf, Bertrand, Canepa, Letizia, Fragasso, Alberto, Leyvraz, Serge, Langer, Christian, Ezaydi, Yousef, Vogl, Dan T., Giraldo-Castellano, Pilar, Yoon, Sung-Soo, Zarnitsky, Charles, Escoffre-Barbe, Martine, Lemieux, Bernard, Song, Kevin, Bahlis, Nizar Jacques, Guo, Shien, Monzini, Mara Silva, Ervin-Haynes, Annette, Houck, Vanessa, Facon, Thierry
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Ferrata Storti Foundation 2015
Aiheet:
Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4450629/
https://ncbi.nlm.nih.gov/pubmed/25769541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2014.120121
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia